FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
The ligand-binding domains of steroid receptors convey ligand-dependent regulation to certain proteins to which they are fused. Here we characterize fusion proteins between a site-specific recombinase, FLP, and steroid receptor ligand-binding domains. These proteins convert ligand binding into DNA recombination. Thus, ligand binding is directly coupled to an enzyme activity that is easily measured by DNA rearrangements or heritable genetic changes in marker gene expression, as opposed to the multiple events leading to transcription. Recombination by a FLP-estrogen receptor (FLP-EBD) fusion is activated by all tested estrogens, whether agonists or antagonists, indicating that all induce EBD release from the 90-kDa heat shock protein complex. Altering the distance between FLP and the EBD domain in the fusion proteins, by reducing the included length of the estrogen receptor D domain, affects ligand efficacy. A FLP-EBD with no D domain shows reduced inducibility by agonists and, unexpectedly, complete insensitivity to induction by all antagonists tested. A FLP-EBD including some D domain shows a ligand-inducible phenotype intermediate to those displayed by FLP-EBDs containing all or none of the D domain. Thus, we observed a tethered interference between FLP and the EBD domains that differs depending on the distance between the two domains, the conformations induced by agonists or antagonists, and which presents a previously undetectable distinction between estrogen agonists and antagonists in yeast.
Nichols
M
M
European Molecular Biology Laboratory, Gene Expression Program, Heidelberg, Germany.
Rientjes
J M
JM
Logie
C
C
Stewart
A F
AF
D000595:Amino Acid Sequence; D001425:Bacterial Outer Membrane Proteins / Q000235:genetics* / Q000378:metabolism; D004254:DNA Nucleotidyltransferases / Q000235:genetics* / Q000378:metabolism; D004054:Diethylstilbestrol / Q000737:chemistry / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism; D004965:Estrogen Antagonists / Q000378:metabolism*; D004968:Estrogens, Non-Steroidal / Q000378:metabolism*; D000077267:Fulvestrant; D018841:HSP90 Heat-Shock Proteins / Q000502:physiology; D006589:Hexestrol / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D008024:Ligands; D008969:Molecular Sequence Data; D009256:Nafoxidine / Q000737:chemistry / Q000378:metabolism; D010880:Piperidines / Q000737:chemistry / Q000378:metabolism; D020849:Raloxifene Hydrochloride; D011960:Receptors, Estrogen / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics* / Q000378:metabolism; D013629:Tamoxifen / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism; D013997:Time Factors; D015003:Yeasts
D001425:Bacterial Outer Membrane Proteins; D004965:Estrogen Antagonists; D004968:Estrogens, Non-Steroidal; D018841:HSP90 Heat-Shock Proteins; D008024:Ligands; D010880:Piperidines; D011960:Receptors, Estrogen; D011993:Recombinant Fusion Proteins; D013629:Tamoxifen; D006589:Hexestrol; C016601:afimoxifene; D000077267:Fulvestrant; D020849:Raloxifene Hydrochloride; D009256:Nafoxidine; D004958:Estradiol; D004054:Diethylstilbestrol; D004254:DNA Nucleotidyltransferases; C045119:FLP recombinase